$HQY

Ladd Delano sold $675K of HQY

Ladd Delano (EVP, General Counsel) sold 7,500 shares of HEALTHEQUITY, INC. (HQY) at $90.00 ($0.68M total) on 2026-05-28 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Ladd Delano
Published Jun 1, 2026, 10:02 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 1, 2026, 10:05 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$HQY
Neutral
medium confidence
Mentioned
$HQY
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HQYNeutralLow
01

Why it matters

The main tradable element is the disclosed sale size and the fact it was executed under a pre-arranged plan, which generally lowers interpretive impact.

02

Market read

Routine insider selling disclosure for HQY; sentiment impact is likely limited due to 10b5-1 pre-arrangement.

03

What to watch

Traders may over-weight single insider sales; the more informative signal would be repeated insider selling across multiple officers or changes in buying/selling patterns outside 10b5-1.

Relevance 6/10Novelty 6/10Timing: Filed June 1; sale occurred May 28 (post-disclosure timing for traders).

Background

The article is an SEC Form 4 insider transaction disclosure (open-market sale) by an HQY executive, including whether it was pre-arranged under Rule 10b5-1.

Company-level read

Ticker impact

$HQYNeutralMedium confidence
Context

SEC Form 4 shows HQY EVP & General Counsel Ladd Delano sold 7,500 shares in an open-market transaction under a 10b5-1 plan.

Expected impact

Low likelihood of sustained price impact; any effect is likely short-lived unless followed by additional insider activity or fundamental news.

Evidence & confidence

The filing is a routine insider transaction with a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

Minimal; this is company-specific insider disclosure without sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, the disclosure may be largely mechanical and not meaningfully bearish.

Key entities

  • HEALTHEQUITY, INC.

    Company whose shares were sold by an insider; subject of the SEC Form 4 disclosure.

  • Ladd Delano

    EVP, General Counsel at HEALTHEQUITY; reported open-market sale of 7,500 shares.

Related articles

$HQYMed

HealthEquity rating upgraded by Moody’s on strong cash flow

Moody’s upgraded HealthEquity, Inc. (NASDAQ:HQY) corporate family rating to Ba2 from Ba3 and raised its probability of default rating to Ba2-PD from Ba3-PD. It also upgraded $600 million senior unsecured notes to Ba3 from B1, with outlook changed to stable. Moody’s cited stronger operating cash flow and BenefitWallet integration, plus improved leverage and liquidity.

$HQYMedAI 9/10

HealthEquity Q1 2027 Earnings Call: Complete Transcript - HealthEquity (NASDAQ: HQY)

HealthEquity reported fiscal 2027 first-quarter results, citing 7% year-over-year revenue growth and a record adjusted EBITDA margin of 46%, according to the company. It raised guidance to $1.41–$1.42B revenue and $625–$633M adjusted EBITDA. The firm said it expanded digital engagement and Marketplace, used AI for efficiency, saw HSA assets +19% and new HSA sales +15%, and increased its share repurchase authorization by $1B.